Glucagon in β-blocker and calcium channel blocker overdoses: A systematic review

Journal of Toxicology - Clinical Toxicology

Volumn 41, Issue 5, 2003, Pages 595-602

  Bailey, Benoit ^a  

^a UNIVERSITY OF MONTREAL   (Canada)

Author keywords

Calcium channel blocker; Glucagon; Poisoning; Systematic review; blocker

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; GLUCAGON; PROPRANOLOL; VERAPAMIL;

ATRIOVENTRICULAR BLOCK; CONFERENCE PAPER; CONTINUOUS INFUSION; DRUG OVERDOSE; HEART MUSCLE CONTRACTILITY; HEART OUTPUT; HEART RATE; HUMAN; MEAN ARTERIAL PRESSURE; NONHUMAN; SURVIVAL RATE;

ANIMALIA;

EID: 0041315449     PISSN: 07313810     EISSN: None     Source Type: Journal    
DOI: 10.1081/CLT-120023761     Document Type: Conference Paper

References (54)

1. Davis SN, Granner DK. Insulin, oral hypoglycemic agents, and the pharmacology of the endocrine pancreas. In: Hardman JG, Limbird LE, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. New York: McGraw-Hill, 1996:1487-1517.
2. Farah A, Tuttle R. Studies on the pharmacology of glucagon. J Pharm Exp Ther 1960; 129:49-55.
3. Glick G, Parmsley WW, Wechsler AS, Sonnenblick EH. Glucagon: its enhancement of cardiac performance in the cat and dog and persistence of its action despite beta-receptor blockade with propranonol. Circ Research 1968; 22:789-799.
4. Lucchesi BR. Cardiac actions of glucagon. Circ Research 1968; 22:777-787.
5. Kosinski EJ, Stern N, Malindzak GSJ, Boone E. Glucagon and propranolol (inderal) toxicity. New Engl J Med 1971; 285:1325.
6. Crump BJ, Holt DW, Vale JA. Lack of response to intravenous calcium in severe verapamil poisoning. Lancet 1982; 2:939-940.
7. Howland MA. Glugagon. In: Goldfrank LR, Flomenbaum NE, Lewin NA, Weisman RS, Howland MA, Hoffman RS, eds. Goldfrank's Toxicologic Emergencies. Stamford: Appleton and Lange, 1998:827.
8. Ellenhorn MJ. Ellenhorn's Medical Toxicology. Baltimore: Williams and Wilkins, 1997.
9. Benowitz NL. Propranolol (inderal) and beta-blocker toxicity. In: Haddad LM, Winschester JF, eds. Clinical Management of Poisoning and Drug Overdose. Philadelphia: WB Saunders, 1983:850.
10. Dreisbach RH, Robertson WO. Handbook of Poisoning: Prevention, Diagnosis and Treatment. Norwalk: Appleton and Lange, 1987.
11. Goldfrank LR, Flomenbaum NE, Lewin NA, Weisman RS. Toxicologic Emergencies. A Comprehensive Handbook in Problem Solving. New York: Appleton-Century-Crofts, 1982.
12. Goldfrank LR, Flomenbaum NE, Lewin NA, Weisman RS, Howland MA, Kulberg AG. Goldfrank's Toxicologic Emergencies. Norwalk: Appleton-Century-Crofts, 1986.
13. Howland MA. Glucagon. In: Goldfrank LR, Flomenbaum NE, Lewin NA, Weinstein RS, Howland MA, Kulberg AG, eds. Goldfrank's Toxicologic Emergencies. Norwalk: Appleton-Century-Crofts, 1986:285-286.
14. Howland MA. Glucagon. In: Goldfrank LR, Flomenbaum NE, Lewin NA, Weisman RS, Howland MA, eds. Goldfrank's Toxicologic Emergencies. Norwalk: Appleton and Lange, 1990:378-379.
15. Haddad LM, Shannon MW, Winschester JF. Clinical Management of Poisoning and Drug Overdose. Philadelphia: WB Saunders, 1998.
16. Ford MD, Delaney KA, Ling LJ, Erickson T. Clinical Toxicology. Philadelphia: WB Saunders, 2001.
17. Bryson PD. Comprehensive Review in Toxicology for Emergency Physicians. Washington: Taylor and Francis, 1996.
18. Goldfrank LR, Flomenbaum NE, Lewin NA, Weisman RS, Howland MA, Hoffman RS. Goldfrank's Toxicologic Emergencies. Stamford: Appleton and Lange, 1998.
19. Goldfrank LR, Flomenbaum NE, Lewin NA, Howland MA, Hoffman RS, Nelson L. Goldfrank's Toxicologic Emergencies. New York: McGraw-Hill, 2002.
20. Juni P, Altman DG, Egger M. Assessing the quality of randomised controlled trials. In: Egger M, Smith GD, Altman DG, eds. Systematic Reviews in Health Care - Meta-Analysis in Context. London: BMJ book, 2001:87-108.
21. Love JN, Leasure JA, Mundt DJ, Janz TG. A comparison of amrinone and glucagon therapy for cardiovascular depression associated with propranolol toxicity in a canine model. J Tox Clin Toxicol 1992; 30:399-412.
22. Toet AE, Wemer J, Vleeming W, de Biesebeek JD, Meulenbelt J, de Wildt DJ. Experimental study of the detrimental effect of dopamine/glucagon combination in d,l-propranolol intoxication. Hum Exp Toxicol 1996; 15:411-421.
23. Love JN, Sachdeva DK, Bessman ES, Curtis LA, Howell JM. A potential role for glucagon in the treatment of drug-induced symptomatic bradycardia. Chest 1998; 114:323-326.
24. Stone CK, May WA, Carroll R. Treatment of verapamil overdose with glucagon in dogs. Ann Emerg Med 1995; 25:369-374.
25. Kerns WI, Schroeder D, Williams C, Tomaszewski C, Raymond R. Insulin improves survival in a canine model of acute beta-blocker toxicity. Ann Emerg Med 1997; 29:748-757.
26. Love JN, Hanfling D, Howell JM. Hemodynamic effects of calcium chloride in a canine model of acute propranolol intoxication. Ann Emerg Med 1996; 28:1-6.
27. Sato S, Tsuji MH, Okubo N, Naito H. Milrinone versus glucagon: comparative hemodynamic effects in canine propranolol poisoning. J Tox Clin Toxicol 1994; 32:277-289.
28. Sato S, Tsuji MH, Okubo N, Nishimoto C, Naito H. Combined use of glucagon and milrinone may not be preferable for severe propranolol poisoning in the canine model. J Tox Clin Toxicol 1995; 33: 337-342.
29. Chernow B, Reed L, Geelhoed GW, Anderson M, Teich S, Meyerhoff J, Beardsley D, Lake CR, Holaday JW. Glucagon: endocrine effects and calcium involment in cardiovascular actions in dogs. Circ Shock 1986; 19:393-407.
30. Benvenistry AI, Spotnitz HM, Rose EA, Malm JR, Hoffman BF. Antagonism of chronic canine beta-adrenergic blockade with dopamine-isoproterenol, dobutamine, and glucagon. Surg Forum 1979; 30:187-188.
31. Peterson A, Lucchesi B, Kirsh M. The effects of glucagon in animals on chronic propranolol therapy. Ann Thorac Surg 1978; 25:340-345.
32. Kosinski EJ, Malindzak GSJ. Glucagon and isoproterenol in reversing propranolol toxicity. Arch Inter Med 1973; 132:840-843.
33. Madan BR, Gupta RS, Jain BK. Pulmonary vascular and cardiac effects of glucagon before and after adrenergic beta-receptor blockade. Indian J Physiol Pharmacol 1971; 15:173-177.
34. Brooks H, Banas JSJ, Dalen JE, Dexter L. Cardiovascular and contractile responses to nondepressant beta-adrenergic blockade. Amer J Physiol 1971; 221:138-143.
35. Zaritsky AL, Horowitz M, Chernow B. Glucagon antagonism of calcium channel blocker-induced myocardial depression. Crit Care Med 1988; 16:246-251.
36. Whitsitt LS, Lucchesi BR. Effects of beta-receptor blockade and glucagon on the atrioventricular transmission system in the dog. Circ Research 1968; 23:585-595.
37. Levey GS, Epstein S. Activation of adenyl cyclase by glucagon in cat and human heart. Circ Research 1969; 24:151-156.
38. Jolly SR, Kipnis JN, Lucchesi BR. Cardiovascular depression by verapamil: reversal by glucagon and interactions with propranolol. Pharmacology 1987; 35:249-255.
39. Chernow B, Zaloga GP, Willey SC, Clapper M, Holaday JW. Glucagon's chronotropic action is calcium dependent. J Pharm Exp Ther 1987; 241:833-837.
40. Love JN, Leasure JA, Mundt DJ. A comparison of combined amrinone and glucagon therapy to glucagon alone for cardiovascular depression associated with propranolol toxicity in a canine model. Amer J Emerg Med 1993; 11:360-363.
41. Tuncok Y, Apaydin S, Gidener S, Guven H, Oto O, Ates M, Gure A. The effects of amrinone and glucagon on verapamil-induced myocardial depression in a rat isolated heart model. Gen Pharmacol 1997; 28:773-776.
42. Tuncok Y, Apaydin S, Kalkan S, Ates M, Guven H. The effects of amrinone and glucagon on verapamil-induced cardiovasular toxicity in anesthetized rats. Int J Exp Path 1996; 77:207-212.
43. Stone CK, Thomas SH, Koury SI, Low RB. Glucagon and phenylephrine combination vs glucagon alone in experimental verapamil overdose. Acad Emerg Med 1996; 3:120-125.
44. Kline JA, Tomaszewski CA, Schroeder JD, Raymond RM. Insuline is a superior antidote for cardiovascular toxicity induced by verapamil in the anesthetized canine. J Pharm Exp Ther 1993; 267:744-750.
45. Sabatier J, Pouyet T, Shelvey G, Cavero I. Antagonistic effects of epinephrine, glucagon and methylatropine but not calcium chloride against atrio-ventricular conduction disturbances produced by high doses of diltiazem, in conscious dogs. Fundam Clin Pharmacol 1991; 5:93-106.
46. Schoffstall JM, Spivey WH, Gambone LM, Shaw RP, Sit SP. Effects of calcium channel blocker overdose-induced toxicity in the conscious dog. Ann Emerg Med 1991; 20:1104-1108.
47. Sauvadet A, Rohn T, Pecker F, Pavoine C. Synergistic actions of glucagon and miniglucagon on Ca2+ mobilization in cardiac cells. Circ Research 1996; 78:102-109.
48. Zaloga GP, Malcolm D, Holaday JW, Chernow B. Glucagon reverses the hypotension and bradycardia of verapamil overdose in rats. Crit Care Med 1985; 13:273.
49. Chernow B, Reed L, Geelhoed GW, Myerhoff J, Lake CR, Beardsley D, Holaday J. Verapamil antagonizes glucagon's chronotropic effect. Circ Shock 1984; 13:96-97.
50. Farah AE. Glucagon and the circulation. Pharmacol Reviews 1983; 35:181-217.
51. Hall-Boyer K, Zaloga GP, Chernow B. Glucagon: hormone or therapeutic agent? Crit Care Med 1984; 12:584-589.
52. Parmsley WW, Glick G, Sonnenblick EH. Cardiovascular effects of glucagon in man. New Engl J Med 1968; 279:12-17.
53. Martin TG. Advanced life support in the poisoned patient (Tox ACLS). In: Ford MD, Delaney KA, Ling LJ, Erickson T, eds. Clinical Toxicology. Philadelphia: WB Saunders, 2001:12-20.
54. Albertson TE, Dawson A, de LaTorre F, Hoffman RS, Hollander JE, Jaeger A, Kerns II W, Martin TG, Ross MP. Tox-ACLS: toxicologic-oriented advanced cardiac life support. Ann Emerg Med 2001; 37: S78-S90.